Treatment of severe chronic graft-versus-host disease with decidual stromal cells and tracing with 111indium radiolabeling

Stem Cells and Development

Volumn 24, Issue 2, 2015, Pages 253-263

  Erkers, Tom ^a   Kaipe, Helen ^a   Nava, Silvia ^a   Molldén, Pia ^a   Gustafsson, Britt ^a   Axelsson, Rimma ^a   Ringdén, Olle ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; FLUTICASONE; HLA DR ANTIGEN; IMATINIB; INDIUM 111; INFLIXIMAB; INTERLEUKIN 17; INTERLEUKIN 4; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; STEROID; TACROLIMUS; INDIUM; ISOTOPE;

ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CASE REPORT; CELL THERAPY; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA; FEMALE; FLOW CYTOMETRY; HLA DR T LYMPHOCYTE; HUMAN; IN VIVO STUDY; ISOTOPE LABELING; LICHENOID; LUNG; MALE; PILOT STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; PUVA; REGULATORY T LYMPHOCYTE; STROMA CELL; T LYMPHOCYTE; YOUNG ADULT; ALLOGRAFT; BLOOD; CELL TRACKING; CHRONIC DISEASE; CLINICAL TRIAL; DECIDUA; FOLLOW UP; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; LEUKEMIA; METABOLISM; MULTIPOTENT STEM CELL; PATHOLOGY; TH17 CELL; TH2 CELL; TRANSPLANTATION;

ALLOGRAFTS; CELL TRACKING; CHRONIC DISEASE; DECIDUA; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INDIUM; ISOTOPES; LEUKEMIA; MULTIPOTENT STEM CELLS; STROMAL CELLS; T-LYMPHOCYTES, REGULATORY; TH17 CELLS; TH2 CELLS;

EID: 84920815551     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2014.0265     Document Type: Article

References (39)

1. Ringden O and HJ Deeg. (1996). Clinical spectrum of graftversus-host disease. In: Graft vs Host Disease. Ferrara JLM, Deeg HJ, Burakoff SJ, eds. Marcel Dekker, Inc., New York, pp. 525-559.
2. Filipovich AH, D Weisdorf, S Pavletic, G Socie, JR Wingard, SJ Lee, P Martin, J Chien, D Przepiorka, et al. (2005). National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 11:945-956.
3. Lee SJ, JP Klein, AJ Barrett, O Ringden, JH Antin, JY Cahn, MH Carabasi, RP Gale, S Giralt, et al. (2002). Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood 100:406-414.
4. Flowers ME, JF Apperley, K van Besien, A Elmaagacli, A Grigg, V Reddy, A Bacigalupo, HJ Kolb, L Bouzas, et al. (2008). A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood 112:2667-2674.
5. Socie G, A Devergie, JM Cosset, JY Pierga, H Esperou, T Girinski and E Gluckman. (1990). Low-dose (one gray) total-lymphoid irradiation for extensive, drug-resistant chronic graft-versus-host disease. Transplantation 49:657-658.
6. Le Blanc K, F Frassoni, L Ball, F Locatelli, H Roelofs, I Lewis, E Lanino, B Sundberg, ME Bernardo, et al. (2008). Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371:1579-1586.
7. Ringden O, M Uzunel, I Rasmusson, M Remberger, B Sundberg, H Lonnies, HU Marschall, A Dlugosz, A Szakos, et al. (2006). Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 81:1390-1397.
8. Parekkadan B, AW Tilles and ML Yarmush. (2008). Bone marrow-derived mesenchymal stem cells ameliorate autoimmune enteropathy independently of regulatory T cells. Stem Cells 26:1913-1919.
9. Sun L, K Akiyama, H Zhang, T Yamaza, Y Hou, S Zhao, T Xu, A Le and S Shi. (2009). Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells 27: 1421-1432.
10. Weng JY, X Du, SX Geng, YW Peng, Z Wang, ZS Lu, SJ Wu, CW Luo, R Guo, et al. (2010). Mesenchymal stem cell as salvage treatment for refractory chronic GVHD. Bone Marrow Transplant 45:1732-1740.
11. Zhou H, M Guo, C Bian, Z Sun, Z Yang, Y Zeng, H Ai and RC Zhao. (2010). Efficacy of bone marrow-derived mesenchymal stem cells in the treatment of sclerodermatous chronic graft-versus-host disease: clinical report. Biol Blood Marrow Transplant 16:403-412.
12. Ringden O. (2013). Mesenchymal stem cells for treatment and prevention of graft-versus-host disease and graft failure after hematopoietic stem cell transplantation and future challenges. In: Mesenchymal Stem Cell Therapy. Chase IG, Vemuri MC, eds. Springer Verlag, Humana Press, New York, pp. 173-206.
13. Erkers T, S Nava, J Yosef, O Ringden and H Kaipe. (2013). Decidual stromal cells promote regulatory T cells and suppress alloreactivity in a cell contact-dependent manner. Stem Cells Dev 22:2596-2605.
14. Karlsson H, T Erkers, S Nava, S Ruhm, M Westgren and O Ringden. (2012). Stromal cells from term fetal membrane are highly suppressive in allogeneic settings in vitro. Clin Exp Immunol 167:543-555.
15. Ringden O, T Erkers, S Nava, M Uzunel, E Iwarsson, R Conrad, M Westgren, J Mattsson and H Kaipe. (2013). Fetal membrane cells for treatment of steroid-refractory acute graft-versus-host disease. Stem Cells 31:592-601.
16. Sarantopoulos S, KE Stevenson, HT Kim, CS Cutler, NS Bhuiya, M Schowalter, VT Ho, EP Alyea, J Koreth, et al. (2009). Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood 113:3865-3874.
17. Kitko CL, JE Levine, BE Storer, X Chai, DA Fox, TM Braun, DR Couriel, PJ Martin, ME Flowers, et al. (2013). Plasma CXCL9 elevations correlate with chronic GVHD diagnosis. Blood 123:786-793.
18. Kobayashi S,MImamura, S Hashino, J Tanaka andMAsaka. (1997). Clinical relevance of serum soluble interleukin-2 receptor levels in acute and chronic graft-versus-host disease. Leuk Lymphoma 28:159-169.
19. Imamura M, S Hashino, H Kobayashi, S Kubayashi, S Hirano, T Minagawa, J Tanaka, Y Fujii, M Kobayashi, et al. (1994). Serum cytokine levels in bone marrow transplantation: synergistic interaction of interleukin-6, interferongamma, and tumor necrosis factor-alpha in graft-versus-host disease. Bone Marrow Transplant 13:745-751.
20. Fujii H, G Cuvelier, K She, S Aslanian, H Shimizu, A Kariminia, M Krailo, Z Chen, R McMaster, et al. (2008). Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group. Blood 111:3276-3285.
21. Pidala J, M Sarwal, S Roedder and SJ Lee. (2014). Biologic markers of chronic GVHD. Bone Marrow Transplant 49:324-331.
22. Dander E, A Balduzzi, G Zappa, G Lucchini, P Perseghin, V Andre, E Todisco, D Rahal, M Migliavacca, et al. (2009). Interleukin-17-producing T-helper cells as new potential player mediating graft-versus-host disease in patients undergoing allogeneic stem-cell transplantation. Transplantation 88:1261-1272.
23. Yamashita K, U Choi, PC Woltz, SF Foster, MC Sneller, FT Hakim, DH Fowler, MR Bishop, SZ Pavletic, et al. (2004). Severe chronic graft-versus-host disease is characterized by a preponderance of CD4(+) effector memory cells relative to central memory cells. Blood 103:3986-3988.
24. D'Asaro M, F Dieli, N Caccamo, M Musso, F Porretto and A Salerno. (2006). Increase of CCR7-CD45RA + CD8 T cells (T(EMRA)) in chronic graft-versus-host disease. Leukemia 20:545-547.
25. Clark FJ, R Gregg, K Piper, D Dunnion, L Freeman, M Griffiths, G Begum, P Mahendra, C Craddock, P Moss and R Chakraverty. (2004). Chronic graft-versus-host disease is associated with increased numbers of peripheral blood CD4 + CD25high regulatory T cells. Blood 103:2410-2416.
26. Arpinati M, G Chirumbolo, G Marzocchi, M Baccarani and D Rondelli. (2008). Increased donor CD86 + CD14 + cells in the bone marrow and peripheral blood of patients with chronic graft-versus-host disease. Transplantation 85:1826-1832.
27. Miura Y, CJ Thoburn, EC Bright, ML Phelps, T Shin, EC Matsui, WH Matsui, S Arai, EJ Fuchs, et al. (2004). Association of Foxp3 regulatory gene expression with graftversus-host disease. Blood 104:2187-2193.
28. Ringden O, M Remberger, U Persson, P Ljungman, A Aldener, E Andstrom, J Aschan, P Bolme, G Dahllof, T Dalianis, et al. (1995). Similar incidence of graft-versushost disease using HLA-A,-B and-DR identical unrelated bone marrow donors as with HLA-identical siblings. Bone Marrow Transplant 15:619-625.
29. Glucksberg H, R Storb, A Fefer, CD Buckner, PE Neiman, RA Clift, KG Lerner and ED Thomas. (1974). Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 18:295-304.
30. Holm AM, GC Riise, L Hansson, L Brinch, O Bjortuft, M Iversen, S Simonsen and Y Floisand. (2013). Lung transplantation for bronchiolitis obliterans syndrome after allo-SCT. Bone Marrow Transplant 48:703-707.
31. Acosta-Rodriguez EV, L Rivino, J Geginat, D Jarrossay, M Gattorno, A Lanzavecchia, F Sallusto and G Napolitani. (2007). Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol 8:639-646.
32. Ringden O, M Uzunel, B Sundberg, L Lonnies, S Nava, J Gustafsson, L Henningsohn and K Le Blanc. (2007). Tissue repair using allogeneic mesenchymal stem cells for hemorrhagic cystitis, pneumomediastinum and perforated colon. Leukemia 21:2271-2276.
33. Ringdén O. (2013). Mesenchymal stem cells for clinical/therapeutic interventions of graft-vesrus-host disease. In: Stem Cell-Dependent Therapies: Mesenchymal Stem Cells in Chronic Inflammatory Disorders. Gross G and T Haüpl, eds. De Gruyter, Berlin, pp. 101-124.
34. Karp JM and GS Leng Teo. (2009). Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell 4:206-216.
35. Chapel A, JM Bertho, M Bensidhoum, L Fouillard, RG Young, J Frick, C Demarquay, F Cuvelier, E Mathieu, et al. (2003). Mesenchymal stem cells home to injured tissues when co-infused with hematopoietic cells to treat a radiation-induced multi-organ failure syndrome. J Gene Med 5:1028-1038.
36. von Bahr L, I Batsis, G Moll, M Hagg, A Szakos, B Sundberg, M Uzunel, O Ringden and K Le Blanc. (2012). Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation. Stem Cells 30:1575-1578.
37. Li Y and F Lin. (2012). Mesenchymal stem cells are injured by complement after their contact with serum. Blood 120:3436-3443.
38. Moll G, I Rasmusson-Duprez, L von Bahr, AM Connolly-Andersen, G Elgue, L Funke, OA Hamad, H Lonnies, PU Magnusson, et al. (2012). Are therapeutic human mesenchymal stromal cells compatible with human blood? Stem cells 30:1565-1574.
39. Gholamrezanezhad A, S Mirpour, M Bagheri, M Mohamadnejad, K Alimoghaddam, L Abdolahzadeh, M Saghari and R Malekzadeh. (2011). In vivo tracking of 111In-oxine labeled mesenchymal stem cells following infusion in patients with advanced cirrhosis. Nucl Med Biol 38:961-967.